Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study-Reference-Cited by-同舟云学术

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Published:2018-05-11 Issue:1 Volume:18 Page:
ISSN:1471-2377
Container-title:BMC Neurology
language:en
Short-container-title:BMC Neurol

Author:

Traboulsee Anthony,Li David K. B.,Cascione Mark,Fang Juanzhi,Dangond Fernando,Miller Aaron

Funder

EMD Serono

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12883-018-1066-8.pdf

Reference21 articles.

1. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.

2. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.

3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–504.

4. Uitdehaag BM, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin. 2011;27:1529–37.

5. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?;Therapeutic Advances in Neurological Disorders;2024-01

2. Contemporary Patterns of High-Efficacy Disease Modifying Therapy Use in Korean Patients with Relapsing-Remitting Multiple Sclerosis;Journal of Multiple Sclerosis and Neuroimmunology;2023-12-31

3. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide;Frontiers in Immunology;2022-09-27